<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256424</url>
  </required_header>
  <id_info>
    <org_study_id>PC CE203/10</org_study_id>
    <nct_id>NCT01256424</nct_id>
  </id_info>
  <brief_title>Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia</brief_title>
  <official_title>A Randomized Phase II Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low/Moderate-grade Cervical Intraepithelial Neoplasia (CIN1 or 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Photocure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Photocure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An effective and safe medical therapy would be most welcome to reduce the need for surgical
      interventions and related adverse events and psychological impact on patients with cervical
      cancer precursors. In this clinical trial, the investigators propose to evaluate the efficacy
      and safety of photodynamic therapy (PDT) using hexaminolevulinate (HAL) for mild to
      moderate-grade CIN (grade 1-2).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Lesion Response Rates of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment.</measure>
    <time_frame>3 months after last treatment</time_frame>
    <description>Lesion response was defined by three variables: Histology, cytology and HPV. Patient response at three months required histology regression to CIN1 or normal, cytology of LSIL or less severe, and HPV negative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of HPV Response of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment.</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>HPV response was defined as clearance of baseline HPV infection, asssessed by genotype</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">262</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>HAL 5% with illumination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HAL PDT 5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HAL 1% with illumination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HAL PDT 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HAL 0.2% with illumination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HAL PDT 0.2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo ointment without illumination</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo without illumination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAL 5% with illumination</intervention_name>
    <description>Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation</description>
    <arm_group_label>HAL 5% with illumination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAL 1% with illumination</intervention_name>
    <description>Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation</description>
    <arm_group_label>HAL 1% with illumination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAL 0.2% with illumination</intervention_name>
    <description>Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation</description>
    <arm_group_label>HAL 0.2% with illumination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ointment without illumination</intervention_name>
    <description>Treatment with a singe dose of 2g placebo ointment, no photoactivation</description>
    <arm_group_label>Placebo ointment without illumination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ectocervical CIN1 or CIN2 as verified by local pathology (biopsy)
             obtained within the last month

          -  Satisfactory colposcopy examination including:

               -  visibility of entire transformation zone including the squamocolumnar junction
                  and

               -  visibility of entire lesion margin

          -  Negative endocervical os by colposcopy

          -  Colposcopical visible lesion at visit 2, before treatment

          -  Patients with an average sized uterine cervix (approximately 27mm diameter) suitable
             for application of the Klemcap

          -  Age 18 or above

          -  Written informed consent signed

        Exclusion Criteria:

          -  Previous treatment of CIN or invasive disease

          -  Lesion(s) extending to the vaginal vault

          -  Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology, malignant
             cells on cytology or histology or other suspicion of either micro-invasive or invasive
             disease

          -  Suspicion of endocervical disease on colposcopy

          -  Current severe pelvic inflammatory disease, severe cervicitis, or other severe
             gynaecological infection as per colposcopy and clinical examination

          -  Undiagnosed vaginal bleeding

          -  History of toxic shock syndrome

          -  Known or suspected porphyria

          -  Known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate
             or aminolevulinic acid)

          -  Pregnancy, or intention to become pregnant during the study period

          -  Nursing

          -  Childbirth or miscarriage within six weeks of enrolment

          -  Use of heart pacemaker

          -  Participation in other clinical studies either concurrently or within the last 30 days

          -  Risk of poor protocol compliance. Patient participation should be considered with
             respect to living far away from the hospital, plans for moving to another city/state,
             frequent travelling, planning to become pregnant, drug abuse/alcoholic, difficult
             working hours, family obligations, other illness (e.g. psychiatric), etc.

          -  Unwillingness to use adequate birth control (not abstinence) from screening until last
             PDT

          -  Patient is the investigator or any sub-investigator, research assistant, pharmacist,
             study coordinator, other staff or relative thereof directly involved in the conduct of
             the protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Hillemanns, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Hannover</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2010</study_first_posted>
  <results_first_submitted>August 6, 2014</results_first_submitted>
  <results_first_submitted_qc>August 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2014</results_first_posted>
  <last_update_submitted>April 8, 2016</last_update_submitted>
  <last_update_submitted_qc>April 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CIN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HAL 5% With Illumination</title>
          <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 5% ointment followed by photoactivation</description>
        </group>
        <group group_id="P2">
          <title>HAL 1% With Illumination</title>
          <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 1% ointment followed by photoactivation</description>
        </group>
        <group group_id="P3">
          <title>HAL 0.2% With Illumination</title>
          <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 0.2% ointment followed by photoactivation</description>
        </group>
        <group group_id="P4">
          <title>Placebo Ointment Without Illumination</title>
          <description>Treatment with a singe dose of 2g placebo ointment, no photoactivation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HAL 5% With Illumination</title>
          <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 5% ointment followed by photoactivation</description>
        </group>
        <group group_id="B2">
          <title>HAL 1% With Illumination</title>
          <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 1% ointment followed by photoactivation</description>
        </group>
        <group group_id="B3">
          <title>HAL 0.2% With Illumination</title>
          <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 0.2% ointment followed by photoactivation</description>
        </group>
        <group group_id="B4">
          <title>Placebo Ointment Without Illumination</title>
          <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g placebo ointment, no photoactivation</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="62"/>
            <count group_id="B4" value="68"/>
            <count group_id="B5" value="262"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Lesion Response Rates of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment.</title>
        <description>Lesion response was defined by three variables: Histology, cytology and HPV. Patient response at three months required histology regression to CIN1 or normal, cytology of LSIL or less severe, and HPV negative.</description>
        <time_frame>3 months after last treatment</time_frame>
        <population>Patients with CIN2 at baseline, based on central histology review</population>
        <group_list>
          <group group_id="O1">
            <title>HAL 5% With Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 5% ointment followed by photoactivation</description>
          </group>
          <group group_id="O2">
            <title>HAL 1% With Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 1% ointment followed by photoactivation</description>
          </group>
          <group group_id="O3">
            <title>HAL 0.2% With Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 0.2% ointment followed by photoactivation</description>
          </group>
          <group group_id="O4">
            <title>Placebo Ointment Without Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g placebo ointment, no photoactivation</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Lesion Response Rates of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment.</title>
          <description>Lesion response was defined by three variables: Histology, cytology and HPV. Patient response at three months required histology regression to CIN1 or normal, cytology of LSIL or less severe, and HPV negative.</description>
          <population>Patients with CIN2 at baseline, based on central histology review</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of HPV Response of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment.</title>
        <description>HPV response was defined as clearance of baseline HPV infection, asssessed by genotype</description>
        <time_frame>3 months after treatment</time_frame>
        <population>Patients with CIN2 at baseline, based on central histology read, and HPV positive at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>HAL 5% With Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 5% ointment followed by photoactivation</description>
          </group>
          <group group_id="O2">
            <title>HAL 1% With Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 1% ointment followed by photoactivation</description>
          </group>
          <group group_id="O3">
            <title>HAL 0.2% With Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 0.2% ointment followed by photoactivation</description>
          </group>
          <group group_id="O4">
            <title>Placebo Ointment Without Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g placebo ointment,no photoactivation</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of HPV Response of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment.</title>
          <description>HPV response was defined as clearance of baseline HPV infection, asssessed by genotype</description>
          <population>Patients with CIN2 at baseline, based on central histology read, and HPV positive at baseline</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Comparison of Response Rates of Three Different Doses of HAL PDT and Placebo at 6 Months After First Treatment.</title>
        <description>Response was defined as absence of HSIL, and absence of oncogenic HPV if LSIL.</description>
        <time_frame>6 months after first treatment</time_frame>
        <population>Patients diagnosed with HSIL histology by a panel of pathologists were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>HAL 5% With Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 5% ointment followed by photoactivation</description>
          </group>
          <group group_id="O2">
            <title>HAL 1% With Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 1% ointment followed by photoactivation</description>
          </group>
          <group group_id="O3">
            <title>HAL 0.2% With Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 0.2% ointment followed by photoactivation</description>
          </group>
          <group group_id="O4">
            <title>Placebo Ointment Without Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g placebo ointment,no photoactivation</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Response Rates of Three Different Doses of HAL PDT and Placebo at 6 Months After First Treatment.</title>
          <description>Response was defined as absence of HSIL, and absence of oncogenic HPV if LSIL.</description>
          <population>Patients diagnosed with HSIL histology by a panel of pathologists were included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Comparison of Response Rates of Three Different Doses of HAL PDT and Placebo at 9 Months After First Treatment</title>
        <description>Response was defined as absence of HSIL, and absence of oncogenic HPF if LSIL</description>
        <time_frame>9 months after first treatment</time_frame>
        <population>Patients diagnosed with HSIL histology by a panel of pathologists were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>HAL 5% With Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 5% ointment followed by photoactivation</description>
          </group>
          <group group_id="O2">
            <title>HAL 1% With Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 1% ointment followed by photoactivation</description>
          </group>
          <group group_id="O3">
            <title>HAL 0.2% With Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 0.2% ointment followed by photoactivation</description>
          </group>
          <group group_id="O4">
            <title>Placebo Ointment Without Illumination</title>
            <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g placebo ointment,no photoactivation</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Response Rates of Three Different Doses of HAL PDT and Placebo at 9 Months After First Treatment</title>
          <description>Response was defined as absence of HSIL, and absence of oncogenic HPF if LSIL</description>
          <population>Patients diagnosed with HSIL histology by a panel of pathologists were included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>HAL 5% With Illumination</title>
          <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 5% ointment followed by photoactivation</description>
        </group>
        <group group_id="E2">
          <title>HAL 1% With Illumination</title>
          <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 1% ointment followed by photoactivation</description>
        </group>
        <group group_id="E3">
          <title>HAL 0.2% With Illumination</title>
          <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g HAL 0.2% ointment followed by photoactivation</description>
        </group>
        <group group_id="E4">
          <title>Placebo Ointment Without Illumination</title>
          <description>Cervical PDT using Hexaminolevulinate: Treatment with a singe dose of 2g placebo ointment, no photoactivation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <description>Adnexitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Local discomfort</sub_title>
                <description>Includes pelvic pain, vulvovaginal discomfort, vulvovaginal burning sensation, vulvovaginal pain, genital pain, uterine cervical pain, uterine spasm, abdominal pain/discomfort, procedural pain, post procedural discomfort</description>
                <counts group_id="E1" events="33" subjects_affected="24" subjects_at_risk="65"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Discharge</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="65"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Spotting</sub_title>
                <description>Includes vaginal haemorrhage, cervix haemorrhage uterine and metrorrhagia</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Local infection</sub_title>
                <description>Includes vaginal infection, cervicitis, fungal/mycotic infections, vulvitis and trichomonasis</description>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Research and Development</name_or_title>
      <organization>Photocure</organization>
      <phone>+47 22062210</phone>
      <email>ifh@photocure.no</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

